1FW

Dkt. 41426-GC/JPW/BJA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Warren D.W. Heston et al.

Serial No.: 10/614,625 Group Art Unit: 1649

Filed: July 2, 2003 Examiner: C. Borgeest

For: PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND

USES THEREOF

1185 Avenue of the Americas New York, New York 10036 June 7, 2006

Mail Stop Amendment Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the documents identified below, item nos. 3-7 of which are also listed on the attached Form PTO-1449 (EXHIBIT A). Copies of the documents identified below as items 1-7 are attached hereto as EXHIBITS 1 to 7, respectively:

- 1. Notification of Provision of Information mailed March 7, 2006 by Japanese Patent Office to applicants' Japanese representatives in connection with Japanese Patent Application No. 1994-511426 informing these Japanese representatives that a third party had submitted a "Prior Art Document List" and an English language translation of the Notification; (Exhibit 1)
- Prior Art Document List submitted by a third party in connection with Japanese Patent Application No.

Applicants: Warren D.W. Heston, et al.

Serial No.: 10/614,625 Filed: July 2, 2003

Page 2

1994-511426 and an English language translation thereof; (Exhibit 2)

- 3. Chandler et al., (1986) Pteroylpolyglutamate
 Hydrolase from Human Jejunal Brush Borders, J.
 Biol. Chem., 261(2)928-933; (Exhibit 3)
- 4. Silver, D.A. et al., Prostate-Specific Membrane Antigen Expression in Normal and Malignant Human Tissues, Clin. Cancer Res. (1997) 3:81-85; (Exhibit 4)
- 5. Chang, S.S. et al., Five Different Anti-ProstateSpecific membrane Antigen (PSMA) Antibodies
 Confirm PSMA Expression in Tumor-Associated
 Neovasculature, Cancer Res. (1999) 59:3192-3198;
 (Exhibit 5)
- 6. Lerner, R.A., Antibodies of Predetermined Specificity in Biology and Medicine, (1984)
 Advances in Immunology 36:1-44; (Exhibit 6) and
- 7. Brinkmann, U. et al., A Recombinant Immunotoxin Containing a Disulfide-Stabilized Fv Fragment, PNAS, 60(16):7538-7542 (1993). (Exhibit 7)

Applicants note that item no. 3 above was first cited in the Prior Art Document List (item no. 2 above). existence of the Prior Art Document List was first communicated to applicants in the March 7, 2006 Notification of Provision of Information (item no. 1 above) issued by the Japanese Patent Office in connection Japanese Patent Application No. 1994-511426. Applicants further note that a second reference listed in the Prior Art Document List, namely Halstead et al. (1998), was previously disclosed in an Information Applicants: Warren D.W. Heston, et al.

Serial No.: 10/614,625 Filed: July 2, 2003

Page 3

Disclosure Statement filed June 14, 2004 in connection with the above-identified application.

This Supplemental Information Disclosure Statement is being submitted under 37 C.F.R. §1.97(b)(3).

If a telephone conference would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment Commissioner for Patents P.O. Box 1450

John P. White

lexandria

Reg. No. 28,678

Date

John White

Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400